Rethinking influenza

Science

Volumn 326, Issue 5949, 2009, Pages 50-

  Rappuoli, Rino ^a   Del Giudice, Giuseppe ^a   Nabel, Gary J ^b   Osterhaus, Albert D M E ^c   Robinson, Robin ^d   Salisbury, David ^e   Stöhr, Klaus ^f   Treanor, John J ^g  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Novartis Vaccines and Diagnostics Inc   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; ANTIVIRUS AGENT; IMMUNOLOGICAL ADJUVANT;

DISEASE TREATMENT; INFLUENZA; RECONSTRUCTION; SUSTAINABILITY;

DISEASE TRANSMISSION; EMULSION; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; PRIORITY JOURNAL; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH ORGANIZATION; ANIMAL; ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EPIDEMIC; HEALTH SURVEY; IMMUNOLOGY; MASS IMMUNIZATION; ORTHOMYXOVIRUS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIVIRAL AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS IMMUNIZATION; ORTHOMYXOVIRIDAE; POPULATION SURVEILLANCE;

EID: 70349661983     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1179475     Document Type: Short Survey

References (12)

1. International Federation of Pharmaceutical and Manufacturers & Associations, presentation at Influenza Vaccines for the World (IVW) 2009, Cannes, France, 27 to 30 April 2009; www.ifpma.org/lnfluenza/content/pdfs/ Presentations/2009-04-27-Bridging-the-Gap-Cannes.pdf.
2. J.J.Treanor, J. D. Campbell, K. M. Zangwill, T. Rowe, M. Wolff, N. Engl. J. Med. 354, 1343 (2006).
3. I. Leroux-Roels et al., Lancet 370, 580 (2007).
4. G. Galli et al., Proc. Natl. Acad. Sci. U.S.A. 106, 7962 (2009).
5. H. J. Ehrlich et al., N. Engl. J. Med. 358, 2573 (2008).
6. H. R. Greenberg et al., N. Engl. J. Med. (2009).
7. T. W. Clark et al., N. Engl. J. Med. (2009).
8. WHO, "Update on A(H1N1) pandemic and seasonal vaccine availability" (WHO, Geneva, 2009), www.who.int/ immunization/sage/3.MPK- SAGE-7July.pdf
9. W. Abdullah Brooks et al., Emerg. Infect. Dis. 13, 1507 (2007).
10. K. Zaman et al., N. Engl. J. Med. 359, 1555 (2008).
11. Live attenuated vaccines for seasonal vaccination are approved for immunization of individuals 2 to 49 years of age and do not cover the elderly and infants below 2 years of age.
12. The views expressed represent those of the authors, but do not necessarily reflect those of their institutions. They also do not constitute an endorsement of a specific commercial product.